Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004147 · ClinicalTrials.gov registry record · Phase 1
COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors
A Phase 1 study, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004147 is a Phase 1 study that has completed, run by New Approaches to Brain Tumor Therapy Consortium.
The verdict
NCT00004147, a Phase 1 study, has completed, sponsored by New Approaches to Brain Tumor Therapy Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following radiation therapy or chemotherapy.
Interventions
- DRUG incyclinide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004147
The ClinicalTrials.gov registry entry for NCT00004147 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is New Approaches to Brain Tumor Therapy Consortium, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which incyclinide is the first listed.
NCT00004147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004147 about?
NCT00004147 is a clinical study titled "COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors". RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following radiation therapy or chemotherapy.
What is the current status of trial NCT00004147?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00004147?
The interventions under investigation include: incyclinide (DRUG).
Who is sponsoring clinical trial NCT00004147?
This trial is sponsored by New Approaches to Brain Tumor Therapy Consortium, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.